别福鑫;魏盈;吕玉凤;吴珊珊;王丹丹;张丽;

• 1:牡丹江医学院附属红旗医院

摘要(Abstract)：

支气管扩张剂是治疗慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)的核心,且被慢性阻塞性肺疾病全球创议(GOLD)推荐为首选治疗方案。长效抗胆碱能药物(LAMA)及长效β2受体激动剂(LABA)较短效药物疗效更佳,但许多患者在使用单药治疗时仍不能达到满意的临床疗效。LAMA和LABA联合治疗可增加疗益,同时最大限度地减少了使用长效支气管扩张剂治疗时产生的剂量依赖性副作用。TOvi TO试验已经研究了吸入联合制剂噻托溴铵和奥达特罗对于治疗COPD的益处。通过对比健康人群组及呼吸困难组(单药治疗及安慰剂治疗),噻托溴铵/奥达特罗5/5ug治疗能够显著改善FEV1在0～3h的曲线下面积(AUC0～3),增加肺功能测定时的吹气时间,降低肺动态顺应性。在以上及其他研究的基础上,2017年GOLD指南推荐B组和C组COPD患者如症状持续存在或者进一步恶化则使用双联支气管扩张剂治疗,并将其作为D组患者的初始治疗。

关键词(KeyWords)： COPD;噻托溴铵;奥达特罗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 别福鑫;魏盈;吕玉凤;吴珊珊;王丹丹;张丽;

Email:

DOI: 10.13799/j.cnki.mdjyxyxb.2019.01.037

参考文献(References)：

• [1]VOGELMEIER C F,CRINER G J,MARTINEZ F J,et al.Global Strategy for the Diagnosis,Management,and Prevention of Chronic Obstructive Lung Disease 2017 Report.GOLD Executive Summary[J].American journal of respiratory and critical care medicine,2017,195(5):557-582.
• [2]TASHKIN D,CELLI B,SENN S,et al.A 4-year trial of tiotropium in chronic obstructive pulmonary disease[J].N Engl J Med,2008,359(15):1543-1554.
• [3]PISI R,AIELLO M,ZANINI A,et al.Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease[J].International journal of chronic obstructive pulmonary disease,2015,10:1191-1197.
• [4]WALKER P,CALVERLEY P.The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease[J].COPD,2008,5(3):147-152.
• [5]CALVERLEY P.AJRCCM:100-Year Anniversary.Physiology and Chronic Obstructive Pulmonary Disease in the Blue Journals[J].Am J Respir Crit Care Med,2017,195(9):1088-1090.
• [6]JONES P,DONOHUE J,NEDELMAN J,et al.Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease:a pooled analysis[J].Respir Res,2011,12:161.
• [7]DONOHUE J,JONES P,BARTELS C,et al.Correlations between FEV1 and patient-reported outcomes:A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease[J].Pulm Pharmacol Ther,2018,49:11-19.
• [8]RAM F,SESTINI P.Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease:Cochrane systematic review and meta-analysis[J].Thorax,2003,58(7):580-584.
• [9]CHAPMAN K R,RENNARD S I,DOGRA A,et al.Long-term safety and efficacy of indacaterol,a long-acting beta(2)-agonist,in subjects with COPD:a randomized,placebo-controlled study[J].Chest,2011,140(1):68-75.
• [10]KERWIN E,D'URZO A,GELB A,et al.Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPDpatients(ACCORD COPD I)[J].COPD,2012,9(2):90-101.
• [11]BEEH K,SINGH D,DI SCALA L,et al.Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD:the GLOW3 trial[J].International journal of chronic obstructive pulmonary disease,2012,7:503-513.
• [12]MALTAIS F,CELLI B,CASABURI R,et al.Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD[J].Respir Med,2011,105(4):580-587.
• [13]HALPIN D,VOGELMEIER C,PIEPER M,et al.Effect of tiotropium on COPD exacerbations:A systematic review[J].Respir Med,2016,114:1-8.
• [14]BUSCH P J,LAIN D.Inhaled long-acting muscarinic antagonists in chronic obstructive pulmonary disease[J].Future Med Chem,2011,3(13):1623-1634.
• [15]KEATING G.Tiotropium bromide inhalation powder:a review of its use in the management of chronic obstructive pulmonary disease[J].Drugs,2012,72(2):273-300.
• [16]BOUYSSOU T,CASAROSA P,NALINE E,et al.Pharmacological characterization of olodaterol,a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models[J].J Pharmacol Exp Ther,2010,334(1):53-62.
• [17]FERGUSON G,FELDMAN G,HOFBAUER P,et al.Efficacy and safety of olodaterol once daily delivered via Respimatin patients with GOLD 2-4 COPD:results from two replicate 48-week studies[J].International journal of chronic obstructive pulmonary disease,2014,9:629-645.
• [18]KOCH A,PIZZICHINI E,HAMILTON A,et al.Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimatversus placebo and formoterol twice daily in patients with GOLD 2-4 COPD:results from two replicate 48-week studies[J].International journal of chronic obstructive pulmonary disease,2014,9:697-714.
• [19]DRANSFIELD M,BAILEY W,CRATER G,et al.Disease severity and symptoms among patients receiving monotherapy for COPD[J].Prim Care Respir J,2011,20(1):46-53.
• [20]SINGH D.New combination bronchodilators for chronic obstructive pulmonary disease:current evidence and future perspectives[J].Br J Clin Pharmacol,2015,79(5):695-708.
• [21]TASHKIN D,FERGUSON G.Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease[J].Respir Res,2013,14:49.
• [22]COHEN J,MILE S M,DONOHUE J,et al.Dual therapy strategies for COPD:the scientific rationale for LAMA+LABA[J].International journal of chronic obstructive pulmonary disease,2016,11:785-797.
• [23]AALBERS R,MALEKI M R,HAMILTON A,et al.Randomized,Double-Blind,Dose-Finding Study for Tiotropium when Added to Olodaterol,Administered via the Respimat(R)Inhaler in Patients with Chronic Obstructive Pulmonary Disease[J].Advances in therapy,2015,32(9):809-822.
• [24]ZUWALLACK R,ALLEN L,HERNANDEZ G,et al.Efficacy and safety of combining olodaterol Respimat()and tiotropium HandiHaler()in patients with COPD:results of two randomized,double-blind,active-controlled studies[J].International journal of chronic obstructive pulmonary disease,2014,9:1133-1144.
• [25]BRAND P,HEDERER B,AUSTEN G,et al.Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique[J].International journal of chronic obstructive pulmonary disease,2008,3(4):763-770.
• [26]BUHL R,MALTAIS F,ABRAHAMS R,et al.Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD(GOLD 2-4)[J].Eur Respir J,2015,45(4):969-979.
• [27]FERGUSON G,FLEZAR M,KORN S,et al.Efficacy of Tiotropium+Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity:A Post Hoc Analysis[J].Advances in therapy,2015,32(6):523-536.
• [28]FERGUSON G,KARPEL J,CLERISME B E,et al.Efficacy and safety of tiotropium+olodaterol maintenance treatment in patients with COPD in the TONADO and OTEMTO studies:a subgroup analysis by age[J].International journal of chronic obstructive pulmonary disease,2016,11:2701-2710.
• [29]THOMAS M,HALPIN D,MIRAVITLLES M.When is dual bronchodilation indicated in COPD?[J].International journal of chronic obstructive pulmonary disease,2017,12:2291-305.
• [30]DONOHUE J,SINGH D,MUNZU C,et al.Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses:Results from two randomised controlled trials[J].Respir Med,2016,112:65-74.
• [31]VOGELMEIER C,GAGA M,AALAMIAN M M,et al.Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD:the CRYSTAL open-label randomised trial[J].Respir Res,2017,18(1):140.
• [32]TOY E,BEAULIEU N,MCHALE J,et al.Treatment of COPD:relationships between daily dosing frequency,adherence,resource use,and costs[J].Respir Med,2011,105(3):435-441.